## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Han,	et	al
ADDIIGAHIS.	i icii,	Ci	QI.

Serial No. Not Yet Assigned

Filed: July 28, 2006

For: HIV INTEGRASE INHIBITORS

Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- 4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

DATE OF DEPOSIT

DEPOSIT

HEREBY CERTIFY THAT THIS CORRESPONDENCE IS

BEING DEPOSITED WITH THE UNITED STATES POSTAL

ERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"

ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO

COMMISSIONER FOR PATENTS, P.O. BOX 1450,

ALEXANDRIA, VIRGINIA 22313-1450.

MAILED BY

DATE 1 1 ST A

PATENT Case No. 21515YP

## INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

	RELATED APPLICATION						
	U. S. SERIAL NUMBER	FILING DATE	MERCK CASE				
If th	nis is inconvenient, additional copies will be submitted upon request						
	6. In accordance with 37 C.F.R. 1.97, (check one)						
	the attached information is filed within three months of the filing da	te of the captioned case.					
	the attached information is filed more than three months after the f Office Action on the merits.	iling date but prior to the m	nailing of a first				
	the attached information is filed before the mailing of a first Office a examination under §1.114.	action after the filing of a re	equest for continued				
	the attached information is being filed more than three months after Office Action on the merits, but before the mailing date of a Final Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).	action, Notice of Allowance	, or an action that				
	each item of information contained in this Information Disclosure S from a foreign patent office in a counterpart foreign application not Statement.		•				
	each item of information contained in the information disclosure state a foreign patent office in a counterpart application and this commundesignated in §1.56(c) more than thirty days prior to the filing of the	nication was not received	by any individual				
	no item of information contained in this Information Disclosure States foreign patent office in a counterpart foreign application, and, to the after making reasonable inquiry, was known to any individual designments prior to the filing of this Statement.	e knowledge of the person	signing the certification				

Respectfully submitted,

Levelle R. Walton

By: Kenneth R. Walton

Attorney For Applicant(s)

Reg. No. 32,951

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-3462

Date: July 28, 2006

Approved for use through 781 C006 OMB 085 0 SUBSTITUTE for PTO/SB/08A (07-05), Information Disclosure Statement by Applicant Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

				Patent and Trademark Office, 0.5 DEFARTMENT OF COMMUNICE
Substitute for form 1449A/PTO INFORMATION DISCLOSUR STATEMENT BY APPLICANT  (use as many sheets as necessary)  t		IAP	COMPLETE HUNDHNU 28 JUL 2006	
	CLOSURE	Application Number	Not Yet Assigned	
TATEREST DA	7 A D	DIICANT	Application Number Not Yet Assigned Filing Date July 28, 2006	
STATEMENT BY APPLICANT		First Named Inventor	Wei Han	
		,	Group Art Unit	Not Yet Assigned
(use as many sheets	s as n	ecessary)	Examiner Name	Not Yet Assigned
1	of	2	Attorney Docket Number	21515YP
	NFORMATION TATEMENT BY	NFORMATION DIS TATEMENT BY AP  (use as many sheets as n	TATEMENT BY APPLICANT  (use as many sheets as necessary)	NFORMATION DISCLOSURE  TATEMENT BY APPLICANT  Filing Date  First Named Inventor  Group Art Unit  (use as many sheets as necessary)  Examiner Name

U.S. PATENT DOCUMENTS							
Examiner Cite		U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		
	1	6,380,249	B1	Young, et al.	04/30/2002		
	2	6,306,891	B1	Selnick, et al.	10/23/2001		
	3	6,262,055	B1	Young, et al.	07/17/2001		
	4	2003/0055071	A1	Anthony, et al.	03/20/2003		
	5	2005/0054645	Al	Miyazaki, et al.	03/10/2005		
	6	2006/0052361	Al	Miyazaki, et al.	03/09/2006		
	7	2004/0229909	Al	Kiyama, et al.	11/18/2004		
	<del></del>						
				<del></del>			

			Foreign Patent Documen	nt		Date of Publication of
Examiner Initials*	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY
	8	wo	01/00578	A1	Tularik, Inc.	01/04/2001
	9	EP	1422218	Al	Shionogi & Co., Ltd.	05/26/2004
	10	wo	02/30426	Al	Merck & Co., Inc.	04/18/2002
	11	wo	02/55079	A2	Merck & Co., Inc.	07/18/2002
	12	wo	02/036734	A2	Merck & Co., Inc.	05/10/2002
	13	wo	03/35076	Al	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S P A	05/01/2003
	14	wo	03/35077	Al	Angeletti S.P.A. Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A	05/01/2003
	15	wo	03/062204	Al	Merck & Co., Inc.	07/31/2003
	16	wo	04/004657	A2	Bristol-Myers Squibb Co.	01/15/2004

Examiner Signature	Date Considered	

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Approved for the through 1/3 4/2005. ONB 1861 16631
SUBSTITUTE for PTO/SB/08A (07-05), Information Disclosure Statement by Applicant
Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO		AMPLIANCIAN ON PIUZ8 JULZ			
	INFORMATION DISCLOSURE			Application Number	Not Yet Assigned
CTATEMENT DV ADDI ICANT				Filing Date	July 28, 2006
3	STATEMENT BY APPLICANT			First Named Inventor	Wei Han
			,	Group Art Unit	Not Yet Assigned
(use as many sheets as necessary)			ecessary)	Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	21515YP

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.					
	17	Ratner, L., et al., "Complete Nucleotide Sequence of the AIDS Virus, HTLV-III", Nature, Vol. 313, pp. 277-284, (1985)					
	18	Toh, H., et al., "Close Structural Resemblance Between Putative Polymerase of a Drosphila Transposable Genetic Element 17.6 and Pol Gene Product of Moloney Murine Leukemia Virus", EMBO Journal, Vol. 4, No. 5, pp. 1267-1272, (1985)					
	19	Power, M.D., et al., "Nucleotide Sequence of SRV-1, a Type D Simian Acquired Immune Deficiency Syndrome Retrovirus", Science, Vol. 231, pp. 1567-1572, (1986)					
	20	Pearl, L.H., et al., "A Structural Model for the Retroviral Proteases", Nature, Vol. 329, pp. 351-354, (1987)					
	21	Derwent Abstract No. 2003-300600/29, Abstract of WO 03/016275, "Compositions Containing New and Known Heterocyclic Ketone Compounds Useful as Antiviral Agents Especially for Treating HIV Infections (JPN)"					
	22	Derwent Abstract, No.2005-202383/21, Abstract of WO 05/016927, "New Bicyclic Nitrogen Containing Heterocyclic Dione Compounds are Integrase Inhibitors Used for Treating Viral Infections e.g. HIV Infection (JPN)"					
	23	Maurin, C., et al., "Structure-Activity Relationships of HIV-1 Integrase Inhibitors - Enzyme-Ligand Interactions", Current Medicinal Chemistry, Vol. 10, pp. 1795-1810 (2003)					
· · · · · · · · · · · · · · · · · · ·							

Examiner	Date	
Signature	Considered	

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.